List view / Grid view
13 May 2019 | By Christopher Fox, Dr Daniel Hoft
Vaccinations have begun in a phase I human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate. Nikki Withers speaks to Dr Daniel Hoft and Christopher Fox about the formulation process and what this means for vaccine development going forward.
10 May 2019 | By European Pharmaceutical Review
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a CETR grant for tuberculosis drug development.
24 January 2019 | By Nikki Withers (European Pharmaceutical Review)
A vaccine that does not require a cold chain could be much more easily distributed to communities in need…
2 July 2018 | By European Pharmaceutical Review
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, were shown to kill more TB bacteria in sputum cultures without increasing the adverse effects of treatment, according to a recent randomised controlled trial.
25 June 2018 | By European Pharmaceutical Review
Promising experimental cancer chemotherapy drugs may help knock out another life-threatening disease: tuberculosis (TB)...
1 May 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Drug that strengthens blood vessels allows antibiotics to infiltrate tuberculosis granulomas in mice...
6 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new blood test has been found to more accurately predict the development of tuberculosis up to two years before its onset in people living with someone with active TB...
26 February 2018 | By European Pharmaceutical Review
Scientists in California have undertaken studies that have demonstrated the effectiveness of a sophisticated algorithm in preventing the spread of infectious diseases. The application of AI allows authorities to identify the best use of resources and highlight subtle interaction points that might otherwise be missed.
19 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer...
6 December 2017 | By European Pharmaceutical Review
A study by the University of Warwick and the Francis Crick Institute has enabled a deeper understanding of the mechanism of action of antibiotic drug, D-cycloserine, which holds promise for future TB treatment.
22 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
A cheap and widely used drug, used to treat conditions such as heartburn, gastritis and ulcers, could work against the bacteria that cause TB...
13 January 2016 | By Victoria White
The new guidance combines clinical advice and public health guidance for the first time...
16 July 2015 | By Victoria White
Data from a post-hoc subset analysis of Phase IIb clinical trials suggests the potential efficacy of Otsuka’s delamanid for the treatment of XDR-TB...
7 July 2015 | By Victoria White
Testing thousands of approved drugs, EPFL scientists have found that an over-the-counter antacid, lansoprazole, may be an effective anti-tuberculosis drug...
6 November 2014 | By European Pharmaceutical Review
Janssen Research & Development, LLC (Janssen) today announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO® (bedaquiline) in the STREAM Study. The STREAM study is an ongoing, multi-centre international randomized controlled trial to evaluate a standardized treatment regimen of anti-tuberculosis drugs for patients…
Follow: